拓新药业
(301089)
| 流通市值：32.81亿 | | | 总市值：52.63亿 |
| 流通股本：7888.24万 | | | 总股本：1.27亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 108,322,506.68 | 835,509,951.28 | 746,127,863.8 | 656,976,189.03 |
| 营业收入 | 108,322,506.68 | 835,509,951.28 | 746,127,863.8 | 656,976,189.03 |
| 二、营业总成本 | 111,604,696.36 | 517,162,283.47 | 366,447,775.5 | 256,091,187.13 |
| 营业成本 | 79,986,578.97 | 351,952,513.76 | 225,736,875.62 | 161,447,781.67 |
| 税金及附加 | 1,277,369.64 | 13,019,674.91 | 11,274,936.23 | 9,736,296.08 |
| 销售费用 | 2,100,833.34 | 9,828,891.09 | 8,985,971.78 | 5,866,581.91 |
| 管理费用 | 20,722,760.06 | 94,474,128.17 | 88,224,590.02 | 59,210,000.26 |
| 研发费用 | 8,246,051.34 | 51,249,522.21 | 34,942,697.26 | 21,932,676.68 |
| 财务费用 | -728,896.99 | -3,362,446.67 | -2,717,295.41 | -2,102,149.47 |
| 其中:利息费用 | 620.52 | 337,069.98 | 285,058.95 | 238,677.7 |
| 其中:利息收入 | 487,280.89 | 3,288,967.15 | 965,427.81 | 1,755,084.43 |
| 加:公允价值变动收益 | -704,998.3 | 546,870.44 | -158,127.86 | 969,161.81 |
| 加:投资收益 | 1,453,695.62 | 6,569,233.69 | 6,288,621.53 | 3,512,683.42 |
| 资产处置收益 | -4,909.59 | - | - | - |
| 资产减值损失(新) | - | -10,768,156.06 | -4,150,028.51 | -3,638,540.29 |
| 信用减值损失(新) | 2,385,995.35 | -4,485,090.22 | -7,013,573.11 | -8,044,783.42 |
| 其他收益 | 2,629,281.78 | 11,473,406.45 | 7,249,159.86 | 3,936,380.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 2,476,875.18 | 321,683,932.11 | 381,896,140.21 | 397,619,903.88 |
| 加:营业外收入 | 29,957.52 | 1,422.95 | 1,422.96 | 422.96 |
| 减:营业外支出 | 54,627.14 | 5,151,985.27 | 2,282,453.71 | 2,036,019.55 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 2,452,205.56 | 316,533,369.79 | 379,615,109.46 | 395,584,307.29 |
| 减:所得税费用 | 383,823.73 | 73,460,635.41 | 66,424,275.94 | 86,051,363.17 |
| 六、净利润 | 2,068,381.83 | 243,072,734.38 | 313,190,833.52 | 309,532,944.12 |
| 持续经营净利润 | 2,068,381.83 | 243,072,734.38 | 313,190,833.52 | 309,532,944.12 |
| 归属于母公司股东的净利润 | 2,068,381.83 | 243,072,734.38 | 313,190,833.52 | 309,532,944.12 |
| (一)基本每股收益 | 0.02 | 1.93 | 2.49 | 2.46 |
| (二)稀释每股收益 | 0.02 | 1.93 | 2.49 | 2.46 |
| 八、其他综合收益 | - | -2,126,356.94 | - | - |
| 归属于母公司股东的其他综合收益 | - | -2,126,356.94 | - | - |
| 九、综合收益总额 | 2,068,381.83 | 240,946,377.44 | 313,190,833.52 | 309,532,944.12 |
| 归属于母公司股东的综合收益总额 | 2,068,381.83 | 240,946,377.44 | 313,190,833.52 | 309,532,944.12 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-25 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |